Status:
COMPLETED
Clinical Outcomes of High Dose Vitamin D Versus Standard Dose in COVID-19 Egyptian Patients
Lead Sponsor:
Ain Shams University
Collaborating Sponsors:
Misr International University
Conditions:
Covid19
Corona Virus Infection
Eligibility:
All Genders
18-65 years
Brief Summary
Vitamin D is a secosteroid hormone which may have beneficial role in reducing COVID-19 adverse outcomes by first regulating the renin angiotensin system (RAS). Recent studies on animal in which acute ...
Eligibility Criteria
Inclusion
- Age 18 to 65 years.
- COVID-19 hospitalized patients with pneumonia confirmed by chest X-ray or CT scan.
- RT-PCR Confirmed infection with COVID-19 or strongly suspected infection with pending confirmation studies.
- Presence of acute respiratory distress syndrome (ARDS).
- Having either peripheral capillary oxygen saturation (SpO2) ≤ 94% ambient air, or a partial oxygen pressure (PaO2) to fraction of inspired oxygen (FiO2) ratio ≤ 300 mmHg.
Exclusion
- Vitamin D supplementation in the previous month.
- Contraindication for vitamin D supplementation: active granulomatosis (sarcoidosis, tuberculosis, lymphoma), history of calcic lithiasis, known hypervitaminosis D or hypercalcemia, known intolerance to vitamin D.
- Organ failure requiring admission to a resuscitation or high dependency unit.
- Pregnant women.
- Participation in another simultaneous clinical trial.
Key Trial Info
Start Date :
December 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 1 2021
Estimated Enrollment :
116 Patients enrolled
Trial Details
Trial ID
NCT04738760
Start Date
December 1 2020
End Date
August 1 2021
Last Update
July 20 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Teachers Hospital
Cairo, Please Select, Egypt, 11314